and Europe for treatment of Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration with hESC-derived RPE cells...ThromboGenics NV, of Leuven, Belgium, reported positive data from a Phase IIa study suggesting that Jetrea (ocriplasmin) offers the potential to resolve symptomatic vitreomacular adhesion (VMA) associated with wet age-related macular degeneration
Ltd., of Tokyo, reported results of a Phase IIa trial of emixustat hydrochloride for geographic atrophy (GA) of dry age-related macular degeneration at the Association for Research in Vision and Ophthalmology meeting in Seattle...Ltd., said Harvard Medical School presented data at the Association for Research in Vision and Ophthalmology conference in Seattle showing a major link between vascular endothelial growth factor (VEGF)-C levels and age-related macular degeneration (AMD) and that assessment
Acucela Inc., of Seattle, said it started a Phase IIb/III trial of emixustat hydrochloride for geographic atrophy associated with dry age-related macular degeneration
StemCells Inc., of Newark, Calif., added the Byers Eye Institute at Stanford University in Palo Alto, Calif., as a second site for the Phase I/II trial of its purified human neural stem cell candidate in dry age-related macular degeneration
The trials will assess safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with Stargardt's macular dystrophy and dry age-related macular degeneration after 12 months
The committee also gave the company permission to proceed in treating patients in additional cohorts recently approved by the FDA for trials in Stargardt's macular dystrophy and dry age-related macular degeneration
Advanced Cell Technology Inc., of Marlborough, Mass., said it is amending the patient treatment protocol for the remainder of its Phase I trials testing human embryonic cell-derived retinal pigment epithelial cells in Stargardt's macular dystrophy and dry age-related macular degeneration to allow patients with better vision, defined as a visual acuity of 20/100 to enroll in the studies
Molecular Partners licensed rights to MP0112 to Allergan Inc., of Irvine, Calif., which is testing the drug in a Phase IIb trial in exudative age-related macular degeneration. (See BioWorld Today, May 11, 2011
Advanced Cell Technology Inc., of Marlborough, Mass., reported evidence of engraftment of transplanted human embryonic stem cell-derived retinal pigment epithelial cells and visual acuity gain in a Phase I/II trial in Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (AMD
A Phase I/II study is in patients with dry age-related macular degeneration, while a separate study is testing the cells in Stargardt's macular dystrophy
OxiGene Inc., of South San Francisco, said data from a Phase II trial of Zybrestat (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), were presented at the annual meeting of the American Academy of Ophthalmology
Advanced Cell Technology Inc., of Santa Monica, Calif., said it has treated 13 patients thus far in its three ongoing trials for dry age-related macular degeneration and Stargardt's disease using human embryonic stem cell-derived retinal pigment epithelial cells
Advanced Cell Technology Inc. (ACT), of Marlborough, Mass., said the independent data and safety monitoring board for its three ongoing trials approved the enrollment and treatment of two additional patients with dry age-related macular degeneration, representing the final patients in the trial's three-patient second cohort
Lpath Inc., of San Diego, started the dosing of iSONEP in its Nexus Phase II study, with several wet age-related macular degeneration (AMD) patients treated since Sept...StemCells Inc., of Newark, Calif., said the first patient was enrolled in its Phase I/II study designed to test the safety and preliminary efficacy of the firm's HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration
Ohr Pharmaceutical Inc., of New York, began a randomized, double-blind, placebo-controlled, Phase II trial of Squalamine Eye Drops for wet, age-related macular degeneration
Oxford BioMedica plc, of Oxford, UK, and partner Sanofi SA, of Paris, reported a positive interim review by the data safety monitoring board (DSMB) of the RetinoStat Phase I study in neovascular, or wet, age-related macular degeneration and the StarGen Phase I/IIa study in Stargardt disease
Advanced Cell Technology Inc., of Marlborough, Mass., treated its fourth patient, or the first in a second cohort, in a Phase I/II trial for dry, age-related macular degeneration with its human embryonic stem cell-derived retinal pigment epithelial cells
Lpath also is studying Asonep in a four-arm, double-blind, Phase II study in patients with wet age-related macular degeneration